Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedFeb 08, 2026
DataAggregated Company Financials
Companies152
  • 7D3.1%
  • 3M-3.1%
  • 1Y-8.8%
  • YTD-0.03%

The Healthcare industry is up 3.1% in the last week, with Swedish Orphan Biovitrum up 17%. In the same time, Vitrolife was down 22%. In contrast, the industry has lost 8.8% in the last 12 months. As for the next few years, earnings are expected to grow by 26% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 08 Feb 2026SEK 582.6bSEK 229.3b-SEK 1,816,881,182.0734x-320.6x2.5x
Tue, 06 Jan 2026SEK 578.8bSEK 230.3bSEK 3.7b40.7x157.6x2.5x
Thu, 04 Dec 2025SEK 588.0bSEK 230.7bSEK 3.6b42.1x164x2.5x
Sat, 01 Nov 2025SEK 610.3bSEK 228.3bSEK 3.3b46.3x183.4x2.7x
Mon, 29 Sep 2025SEK 593.6bSEK 227.1bSEK 6.6b43.5x89.8x2.6x
Wed, 27 Aug 2025SEK 629.5bSEK 227.3bSEK 6.5b47.3x97.6x2.8x
Fri, 25 Jul 2025SEK 638.2bSEK 226.0bSEK 6.4b50.5x99.3x2.8x
Sun, 22 Jun 2025SEK 593.9bSEK 226.9bSEK 5.9b45x101.4x2.6x
Tue, 20 May 2025SEK 610.5bSEK 224.9bSEK 5.6b43.9x109.3x2.7x
Thu, 17 Apr 2025SEK 547.4bSEK 221.8bSEK 5.5b32.7x99.6x2.5x
Sat, 15 Mar 2025SEK 558.6bSEK 206.4bSEK 4.9b37.2x114x2.7x
Mon, 10 Feb 2025SEK 600.9bSEK 220.4bSEK 2.5b42x238.4x2.7x
Wed, 08 Jan 2025SEK 585.5bSEK 202.7b-SEK 2,498,966,853.1541.3x-234.3x2.9x
Fri, 06 Dec 2024SEK 567.9bSEK 202.5b-SEK 2,446,380,573.0937.8x-232.2x2.8x
Sun, 03 Nov 2024SEK 524.9bSEK 200.0b-SEK 2,887,185,216.9836.7x-181.8x2.6x
Tue, 01 Oct 2024SEK 624.6bSEK 200.0b-SEK 2,815,788,245.8340.7x-221.8x3.1x
Thu, 29 Aug 2024SEK 605.4bSEK 199.9b-SEK 2,307,475,072.1639.5x-262.4x3x
Sat, 27 Jul 2024SEK 593.0bSEK 200.1b-SEK 2,851,179,974.0841.4x-208x3x
Mon, 24 Jun 2024SEK 557.3bSEK 195.5b-SEK 3,182,934,253.1735.3x-175.1x2.9x
Wed, 22 May 2024SEK 549.7bSEK 196.2b-SEK 2,898,290,123.2937.1x-189.7x2.8x
Fri, 19 Apr 2024SEK 509.0bSEK 193.2b-SEK 3,150,066,827.0144.5x-161.6x2.6x
Sun, 17 Mar 2024SEK 521.7bSEK 192.3b-SEK 3,668,536,869.5343.5x-142.2x2.7x
Tue, 13 Feb 2024SEK 509.4bSEK 191.0b-SEK 4,141,571,119.4747.8x-123x2.7x
Thu, 11 Jan 2024SEK 551.5bSEK 191.4b-SEK 963,622,982.0047.7x-572.3x2.9x
Sat, 09 Dec 2023SEK 506.7bSEK 190.4b-SEK 1,067,979,885.0051.2x-474.4x2.7x
Mon, 06 Nov 2023SEK 458.1bSEK 190.0b-SEK 1,067,305,617.0040.3x-429.2x2.4x
Wed, 04 Oct 2023SEK 450.0bSEK 185.1b-SEK 2,029,179,031.0034.9x-221.8x2.4x
Fri, 01 Sep 2023SEK 467.2bSEK 185.5b-SEK 2,091,654,234.0038x-223.4x2.5x
Sun, 30 Jul 2023SEK 478.9bSEK 183.8b-SEK 984,749,071.0040.3x-486.3x2.6x
Tue, 27 Jun 2023SEK 474.2bSEK 179.1b-SEK 798,980,189.0043.4x-593.6x2.6x
Thu, 25 May 2023SEK 512.8bSEK 177.7b-SEK 804,181,914.0041.8x-637.6x2.9x
Sat, 22 Apr 2023SEK 511.2bSEK 173.1b-SEK 1,502,209,816.0035x-340.3x3x
Mon, 20 Mar 2023SEK 482.8bSEK 172.4b-SEK 1,416,844,503.0035.9x-340.7x2.8x
Wed, 15 Feb 2023SEK 511.5bSEK 169.4bSEK 476.1m35.9x1074.5x3x
Price to Earnings Ratio

1074.5x


Total Market Cap: SEK 511.5bTotal Earnings: SEK 476.1mTotal Revenue: SEK 169.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -162.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • Total earnings for the Healthcare industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market2.14%
Healthcare3.10%
Life Sciences9.71%
Biotech6.82%
Healthcare Services3.18%
Pharma1.93%
Medical Equipment-0.29%
Healthtech-5.35%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 118x.
    • Analysts are expecting annual earnings growth of 17.5%, which is lower than the prior year's growth of 46.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 36% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 395.8017.4%
+SEK 20.7b		23.3%PE286.2x
GETI B GetingeSEK 203.804.3%
+SEK 2.3b		-4.0%PE24.6x
ALIF B AddLifeSEK 152.0011.4%
+SEK 1.9b		-12.1%PE33.1x
ATT AttendoSEK 100.2012.7%
+SEK 1.6b		67.0%PE17.9x
CAMX CamurusSEK 686.502.8%
+SEK 1.1b		14.4%PE52.4x

Latest News

SOBI
SEK 395.80
Swedish Orphan Biovitrum
7D
17.4%
1Y
23.3%

Swedish Orphan Biovitrum AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08
Swedish Orphan Biovitrum AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ATT
SEK 100.20
Attendo
7D
12.7%
1Y
67.0%

Attendo's (STO:ATT) Upcoming Dividend Will Be Larger Than Last Year's

Feb 08
Attendo's (STO:ATT) Upcoming Dividend Will Be Larger Than Last Year's
RAY B
SEK 179.00
RaySearch Laboratories
7D
-5.9%
1Y
-26.9%
CEVI
SEK 163.00
CellaVision
7D
10.6%
1Y
-18.9%
ALIF B
SEK 152.00
AddLife
7D
11.4%
1Y
-12.1%

AddLife AB (publ) Just Beat EPS By 31%: Here's What Analysts Think Will Happen Next

Feb 07
AddLife AB (publ) Just Beat EPS By 31%: Here's What Analysts Think Will Happen Next
IMP A SDB
SEK 46.20
Implantica
7D
-6.0%
1Y
13.8%
MCAP
SEK 544.00
MedCap
7D
11.0%
1Y
35.3%
SECT B
SEK 208.60
Sectra
7D
-5.3%
1Y
-17.2%

SECT B: Cloud Contracts And Pathology Expansion Will Support Future Upside Potential

Analysts have reaffirmed their price target on Sectra at SEK 245.00, with only marginal tweaks to underlying model inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, supporting an unchanged view of fair value. What's in the News TUM Klinikum in Germany is expanding its Sectra enterprise imaging setup with pathology and ophthalmology modules under a five year contract covering up to 300,000 examinations per year, aimed at higher efficiency and closer collaboration across departments (Client announcement).
GETI B
SEK 203.80
Getinge
7D
4.3%
1Y
-4.0%
ASKER
SEK 77.28
Asker Healthcare Group
7D
2.9%
1Y
n/a
VITR
SEK 90.80
Vitrolife
7D
-21.9%
1Y
-57.6%
EKTA B
SEK 55.40
Elekta
7D
-3.1%
1Y
-16.3%

EKTA B: U.S. Clearance For New Radiotherapy System Will Support Earnings Outlook

Analysts have modestly lifted their price target on Elekta, citing updated assumptions that include a fair value of €88.60 compared with €86.58 previously, a slightly higher discount rate, marginally stronger revenue growth and profit margin expectations, and a lower future P/E multiple. What's in the News Elekta announced that its Elekta Evo CT Linac system has received 510(k) clearance from the U.S. Food and Drug Administration, making the system available to radiation oncology professionals in the United States (Key Developments).
CAMX
SEK 686.50
Camurus
7D
2.8%
1Y
14.4%

CAMX: Obesity Data And Resubmitted NDA Will Drive Future Upside Potential

Analysts have lifted their price target on Camurus from SEK 793.71 to SEK 814.17, citing updated assumptions around revenue growth, margin potential, and a lower future P/E multiple as key drivers of the change. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly treatment and set a PDUFA target action date of 10 June 2026, following an earlier Complete Response Letter related to a third party manufacturing facility (Key Developments).
XVIVO
SEK 201.00
Xvivo Perfusion
7D
-10.7%
1Y
-56.8%

Xvivo Perfusion AB (publ) Just Beat EPS By 134%: Here's What Analysts Think Will Happen Next

Jan 30
Xvivo Perfusion AB (publ) Just Beat EPS By 134%: Here's What Analysts Think Will Happen Next
BIOA B
SEK 306.80
BioArctic
7D
-3.8%
1Y
37.1%

BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access

Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.
BONEX
SEK 171.50
Bonesupport Holding
7D
-7.3%
1Y
-52.0%

BONEX: De Novo Review Shift Will Support Long Term Upside Potential

Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).